Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars

por Alsamil, Ali M., Giezen, Thijs J., Egberts, Toine C., Leufkens, Hubert G., Gardarsdottir, Helga
Publicado 2021